• Humphries B, Xie F. Canada’s amendment to patented drug price regulation: A prescription for global drug cost control? JAMA, 2019 March 29, 2019. Published Online First
  • Xie F, Zoratti M, Chan K, Husereau D, Krahn M, Levine O, Clifford T, Schunemann H, Guyatt G. Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). Medical Decision Making. 2019 Mar 22:272989X19837969.
  • Van Spall HG, Lee SF, Xie F, Oz UE, Perez R, Mitoff PR, Maingi M, Tjandrawidjaja MC, Heffernan M, Zia MI, Porepa L, Panju M, Thabane L, Graham ID, Haynes RB, Haughton D, Simek KD, Ko DT, Connolly SJ. Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial. JAMA 2019; 321(8):753-761.
  • Zoratti MJ, Devji T, Levine O, Thabane L, Xie F. Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. Cancer Treatment Review. 2019;74:43-48.
  • Wu B, Gu X, Zhang Q, Xie F. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. Oncologist. 2019;24(3):349-357.
  • Perreault M, Atkinson SA, Mottola MF, Phillips SM, Bracken K, Hutton EK, Xie F, Meyre D, Morassut RE, Prapavessis H, Thabane L; BHIP Study team. Structured diet and exercise guidance in pregnancy to improve health in women and their offspring: study protocol for the Be Healthy in Pregnancy (BHIP) randomized controlled trial. Trials 2018;19(1):691.
  • Foroutan N, Tarride JE, Xie F, Levine M. A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. ClinicoEconomics and Outcomes Research 2018;126:525-530
  • Law E, Pickard SA, Xie F, Walton S, Lee T, Schwartz A. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Medical Decision Making 2018;38(8):968-982.
  • Kovic B, Jin X, Kennedy SA, Hylands M, Pedziwiatr M, Kuriyama A, Gomaa H, Lee Y, Katsura M, Tada M, Hong BY, Cho SM, Hong PJ, Yu AM, Sivji Y, Toma A, Xie L, Tsoi L, Waligora M, Prasad M, Bhatnagar N, Thabane L, Brundage M, Guyatt G, Xie F. Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analyses. JAMA Internal Medicine 2018;178(12):1586-1596.
  • Jin X, Liu GG, Gerstein HC, Levine MAH, Guan H, Li H, Xie F. Minimally important difference and predictors of change in quality of life as measured using the EQ-5D among Chinese Type 2 Diabetic Patients: A community-based survey in China. Diabetes Metabolism Research and Review. 2018;34(8):e3053.
  • Cox JL, Parkash R, Abidi SS, Thabane L, Xie F, MacKillop J, Abidi SR, Ciaccia A, Choudhri SH, Abusharekh A, Nemis-White J; IMPACT-AF Investigators. Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. American Heart Journal 2018;201:149-157.
  • Zhang Y, Alonso Coello P, Guyatt G, Yepes-Nuñez JJ, Akl EA, Hazlewood G, Pardo-Hernandez H, Etxeandia-Ikobaltzeta I, Qaseem A, Williams JW Jr, Tugwell P, Flottorp S, Chang Y, Zhang Y, Mustafa RA, Rojas MX, Xie F, Schünemann HJ. GRADE Guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences – Inconsistency, Imprecision, and other Domains. Journal of Clinical Epidemiology. 2018 May 22. pii: S0895-4356(17)31061-2.
  • Muratov S, Podbielski DW, Kennedy K, Jack SM, Pemberton J, Ahmed IIK, Baltaziak M, Xie F. Preference-based Glaucoma-specific Health-related Quality of Life Instrument: Development of the Health Utility for Glaucoma. Journal of Glaucoma. 2018;27(7):585-591.
  • Xie F, Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation. Pharmacoeconomics 2018;36(8):883-888.
  • Jin X, Liu GG, Gerstein HC, Levine MAH, Steeves K, Guan H, Li H, Xie F. Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL). Health and Quality of Life Outcomes. 2018 Apr 27;16(1):78. doi: 10.1186/s12955-018-0905-z.
  • Van Spall HG, Lee SF, Xie F, Ko D, Quazi I, Thabane L, Mitoff P, Heffernan M, Maingi M, Porepa L, Tjandrawidjaja M, Zia M, Panju M, Graham I, Haughton D, Connolly S. Knowledge to Action: Rationale and Design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) Stepped Wedge Cluster Randomized Trial. American Heart Journal 2018; 199:75-82.
  • Oremus M, Sharafoddini A, Morgano GP, Jin X, Xie F. A Computer-Assisted Personal Interview App in REDCap for Administering Time Trade-off Surveys: Development and Pretest. JMIR Formative Research 2018;2(1):e3.
  • Richardson J, Tang A, Guyatt G, Thabane L, Xie F, Sahlas D, Hart R, Fleck R, Hladysh G, Macrae L. FIT for FUNCTION: study protocol for a randomized controlled trial. Trials 2018 Jan 15;19(1):39.
  • Graeme B, Xie F, Tarride JE, Economic evaluation of bevacizumab for treatment of platinum resistant recurrent ovarian cancer in Canada. Pharmacoeconomics-Open 2018;2(1):19-29.
  • Kaur MN, Xie F, Shiwcharan A, Patterson L, Shargall Y, Finley CJ, Schieman C, Dalimonte T, Fahim C, Hanna W. Robotic vs. Video-assisted thoracoscopic lung resection during early program development. Annals of Thoracic Surgery 2018;105(4):1050-1057.
  • Tanvejsilp P, Pullenayegum E, Loeb M, Dushoff J, Xie F. Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand. Pharmacoeconomics Open 2018;2(3):281-296.
  • Tanvejsilp P, Loeb M, Dushoff J, Xie F. Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand. Pharmacoeconomics Open 2018;2(3):297-308.
  • Chan KK, Xie F, Willan A, Pullenayegum E, Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size. Medical Decision Making 2018;38(1):26-33.
  • Kaur MN, Xie F, Shiwcharan A, Patterson L, Shargall Y, Finley CJ, Schieman C, Dalimonte T, Fahim C, Hanna W. Robotic vs. Video-assisted thoracoscopic lung resection during early program development. Annals of Thoracic Surgery 2017 In press.
  • Graeme B, Xie F, Tarride JE, Economic evaluation of bevacizumab for treatment of platinum resistant recurrent ovarian cancer in Canada, Pharmacoeconomics-Open 2017 May 29: DOI 10.1007/s41669-017-0030-7.
  • Levine O, Devji T, Xie F. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. Human Vaccine and Immunotherapy. 2017 Aug 3;13(8):1765-1767.
  • Yepes-Nuñez JJ, Zhang Y, Xie F, Alonso-Coello P, Selva A, Schünemann H, Guyatt G. Forty-two systematic reviews generated 23 items for assessing the risk of bias in values and preferences’ studies. Journal of Clinical Epidemiology. 2017 May;85:21-31.
  • Levine O, Devji T, Xie F. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape. Immunotherapy. 2017 Mar;9(5):375-378.
  • Beauchamp MK, Brooks D, Ellerton C, Lee A, Alison J, Camp PG, Dechman G, Haines K, Harrison SL, Holland AE, Marques A, Moineddin R, Skinner EH, Spencer L, Stickland MK, Xie F, Goldstein RS. Pulmonary rehabilitation with balance training for fall reduction in chronic obstructive pulmonary disease: Protocol for a randomized controlled trial. JMIR Research Protocol 2017;6(11):e228
  • Al Sayah F, Qiu W, Xie F, Johnson JA. Comparative performance of the EQ-5D-5L and SF-6D in adults with type 2 diabetes. Quality of Life Research (accepted)
  • Tanvejsilp P, Pullenayegum E, Loeb M, Dushoff J, Xie F. Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand. Pharmacoeconomics Open 2017 https://doi.org/10.1007/s41669-017-0057-9.
  • Tanvejsilp P, Pullenayegum E, Loeb M, Dushoff J, Xie F. Role of pharmaceutical care for self-administered pulmonary tuberculosis treatment in Thailand. Journal of Clinical Pharmacy and Therapeutics. 2017 Mar 19. doi: 10.1111/jcpt.12519. [Epub ahead of print]
  • McClure N, Al Sayah F, Xie F, Luo N, Johnson JA. Instrument-defined estimates of minimally important difference in the EQ-5D-5L index scores. Value in Health 2017;20(2).
  • Al Sayah F, Johnson JA, Ohinmaa A, Xie F, Bansback N. Canadian EQ-5D-5L Valuation Study Group. Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study. Quality of Life Research. 2017 Jan 25. doi: 10.1007/s11136-016-1495-z. [Epub ahead of print]
  • O’Reilly D, Bowen JM, Perampaladas K, Qureshi R, Xie F, Hughes E. Feasibility of an altruistic sperm donation program in Canada: results from a population-based model. Reproductive Health. 2017;14(1):8.
  • Krabbe PF, Stolk EA, Devlin NJ, Xie F, Quik EH, Pickard AS. Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. European Journal of Health Economics. 2017 18(8):967-977.
  • Shortt C, Xie F, Whitlock R, Ma J, Clayton N, Sherbino J, Hill SA, Pare G, McQueen M, Mehta SR, Devereaux PJ, Worster A, Kavsak P. Economic Considerations of Early Rule-In/Rule-Out Algorithms for The Diagnosis of Myocardial Infarction in The Emergency Department Using Cardiac Troponin and Glycemic Biomarkers. Clinical Chemistry. 2016 Nov 3. pii: clinchem.2016.261776. [Epub ahead of print]
  • Xie F, Pullenayegum E, Pickard AS, Ramos Goñi JM, Jo MW, Igarashi A. Transforming Latent Utilities to Health Utilities: East Does Not Meet West. Health Economics. 2016 Oct 16. doi: 10.1002/hec.3444. [Epub ahead of print]
  • Krabbe PF, Stolk EA, Devlin NJ, Xie F, Quik EH, Pickard AS. Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. European Journal of Health Economics. 2016 Nov 2. [Epub ahead of print]
  • Sergei Muratov S, Podbielski D, Jack SM, Ahmed IK, Mitchell L, Baltaziak M, Xie F. Preference-based disease-specific health-related quality of life instrument for glaucoma: a mixed methods study protocol. BMJ Open 2016;6:e012732 doi:10.1136/bmjopen-2016-012732.
  • Devji T, Levine O, Neupane B, Beyene J, Xie F. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Oncology 2016 Oct 27. doi: 10.1001/jamaoncol.2016.4877. [Epub ahead of print]
  • Xie F, Kovic B, Jin X, He X, Wang M, Silvestre C. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies. Pharmacoeconomics 2016 Nov;34(11):1087-1100.
  • Kovic B, Guyatt G, Brundage M, Thabane L, Bhatnagar N, Xie F. Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol. BMJ Open 2016;6:e012909.
  • Oremus M, Xie F, Gaebel K. Development of Clinical Vignettes to Describe Alzheimer’s Disease Health States: A Qualitative Study. PLoS One. 2016 Sep 2;11(9):e0162422.
  • Tarride JE, Breau R, Sharma AM, Hong D, Gmora S, Guertin JR, O’Reilly D, Xie F, Mehran A. The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. Obesity Surgery. 2016 Aug 8. [Epub ahead of print]
  • Tsiplova K, Pullenayegum E, Cooke T, Xie F. EQ-5D-derived health utilities and minimally important differences for chronic health conditions: 2011 Commonwealth Fund Survey of Sicker Adults in Canada. Quality Life Research. 2016;25912):3009-3016.
  • Pullenayegum EM, Sunderland KM, Johnson JA, Xie F; Canadian EQ-5D-5L Valuation Study Group. Handling Regional Variation in Health State Preferences within a Country: A Methodological Framework. Medical Decision Making. 2016 Jun 6. [Epub ahead of print]
  • Samaan Z, Dennis BB, Kalbfleisch L, Bami H, Zielinski L, Bawor M, Litke K, McCabe K, Whattam J, Garrick L, O’Neill L, Tabak TA, Simons S, Chalmers S, Key B, Vanstone M, Xie F, Guyatt G, Thabane L. Behavioral activation group therapy for reducing depressive symptoms and improving quality of life: a feasibility study. Pilot Feasibility Studies. 2016 Apr 29;2:22.
  • Pullenayegum EM, Chan KK, Xie F. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach. Medical Decision Making, 2016; 36(2):223-33.
  • Xie F, Pullenayegum EM, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA on behalf of Canadian EQ-5D-5L Valuation Study Group. A TTO-derived value set of the EQ-5D-5L for Canada, Medical Care, 2016;54(1):98-105.
  • Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA. How different are composite and traditional TTO valuations of severe EQ-5D-5L states? Quality of Life Research 2016 Feb 13. [Epub ahead of print]
  • Oremus M, Xie F, Pullenayegum E, Gaebel K. Can the general public use vignettes to discriminate between Alzheimer’s disease health states? BMC Geriatrics 2016 Feb 3;16(1):36.
  • Chan KK, Xie F, Willan A, Pullenayegum E, Underestimation of variance of predicted health utilities derived from multi-attribute utility instruments: The use of multiple imputation as a potential solution. Medical Decision Making, 2016 May 23. Epub ahead of print.
  • Al Sayah F, Mladenovic A, Gaebel K, Xie F, Johnson JA. How dead is dead? Qualitative findings from participants of combined traditional and lead-time time trade-off valuations. Quality of Life Research, 2016;25(1):35-43.
  • Al Sayah F, Bansback N, Bryan S, Ohinmaa A, Poissant L, Pullenayegum E, Xie F, Johnson JA. Determinants of Time-Trade Off Valuations for EQ-5D-5L Health States: Data from the Canadian EQ-5D-5L Valuation Study. Quality of Life Research 2016;25(7):1679-85.
  • Jin X, Liu GG, Luo N, Li H, Guan H, Xie F. Is bad living better than good death? Impact of demographic and cultural factors on health state preference. Quality of Life Research 2016; 25(4):979-86.
  • Pullenayegum EM, Perampaladas K, Gaebel K, Doble BM, Xie F, Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection? European Journal of Health Economics 2015;16(8):847-855
  • Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Patient-reported health preferences of anticoagulant-related outcomes. Journal of Thrombosis and Thrombolysis 2015;40(3):268-273.
  • Kovic B, Xie F, Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology, 2015; 33(20):2296-2302.
  • Xie F, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D. A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). PharmacoEconomics, 2015;33(8):867-877.
  • Xie F, The Economics of Adalimumab for Ulcerative Colitis. Expert Review in Pharmacoeconomics and Outcomes Research 2015;15(3):373-7.
  • Wang Y, Xie F, Kong MC, Lee LH, Ng HJ, Ko Y. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. Cardiovascular Drugs and Therapy, 2014 Forthcoming.
  • Tan XY, Aung MM, Ngai MI, Xie F, Yu K. Assessment of preference for hormonal treatment-related health states among patients with breast cancer. Value in Health Regional Issue 2014 [Epub ahead of print]
  • Krabbe PF, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS, Xie F. Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values. Medical Care. 2014;52(11):935-943.
  • Li H, Li X, Xie F, Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration. Chinese Journal of Ophthalmology 2014;50(6):426-433.
  • Xie F, Gaebel K, Perampaladas K, Doble B, Pullenayegum E. Comparing EQ-5D valuation studies: A systematic review and methodological reporting checklist. Medical Decision Making 2014;34:8-20.
  • Xie F, Hopkins RB, Burke N, Habib M, De Angelis C, Pasetka M, Giotis A, Goeree R. Time and labour costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: A time and motion study. Hospital Practice 2014;42(2):38-45.
  • Xie F, Pullenayegum E, Gaebel K, Oppe M, Krabbe PF. Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best-worst scaling? European Journal of Health Economics 2014;15(3):281-288.
  • Whelan JP, Bowen JM, Burke N, Woods EA, McIssac GP, Hopkins RB, O’Reilly DJ, Xie F, Sehatzadeh S, Levin L, Mathew SP, Patterson LL, Goeree R, Tarride JE. A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada. Canadian Urology Association Journal 2013 Sep;7(9-10):335-341.
  • Bowen JM, Whelan JP, Hopkins RB, Burke N, Woods EA, McIsaac GP, O’Reilly DJ, Xie F, Sehatzadeh S, Levin L, Mathew SP, Patterson LL, Goeree R, Tarride JE. Photoselective vaporization for the treatment of benign prostatic hyperplasia. Ontario Health Technology Assessment Series. 2013;13(2):1-34.
  • Blackhouse G, Assasi N, Xie F, Gaebel K, Campbell K, Healey JS, O’Reilly D, Goeree R. Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation. International Journal Vascular Medicine. 2013;262809. doi: 10.1155/2013/262809.
  • Smaill F, Jeyanathan M, Smieja M, Medina MF, Thanthrige-Don N, Zganiacz A, Yin C, Heriazon A, Damjanovic D, Puri L, Hamid J, Xie F, Foley R, Bramson J, Gauldie J, Xing Z. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Science Translational Medicine. 2013;5(205):205ra134. doi: 10.1126/scitranslmed.3006843.
  • Doble B, Blackhouse G, Goeree R, Xie F. Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: A Canadian perspective. The Journal of Thoracic and Cardiovascular Surgery, 2013;146(1)52-60.
  • Xie F. Model-based economic evaluation for medical decision making: learn from the past and prepare for the future. Journal of Thoracic Disease 2013;5(3):209-210
  • Xie F. Cost effectiveness of treatment options for early prostate cancer: can we put the puzzle pieces together? European Urology 2013;63(2):411-412.
  • Tarride J-E, Haq M, Nakhai-Pour HR, O’Reilly DJ, Xie F, Dolovich L, Blackhouse G, Goeree R. The excess burden of rheumatoid arthritis in Ontario, Canada. Clinical and Experimental Rheumatology 2013;31(1):18-24.
  • Xie F, Tanvejsilp P, Campbell K, Gaebel K. Cost-effectiveness of pharmaceutical management for osteoarthritis pain: a systematic review of the literature and recommendations for future economic evaluation. Drugs & Aging 2013;30(5):277-284.
  • Pullenayegum E, Xie F. Scoring the 5-Level EQ-5D: Can Latent Utilities Derived from a Discrete Choice Model Be Transformed to Health Utilities Derived from Time Tradeoff Tasks? Medical Decision Making 2013;33(4):567-578.
  • Zhao FL, Xie F, Hu H, Li SC. Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis. Pharmacoeconomics 2013;31:501-508.
  • Xie F, Oremus M, Gaebel K, Measuring Health-related Quality-of-life for Alzheimer’s Disease Using the General Public. Quality of Life Research 2012;21(4):593-601.
  • Sehatzadeh S, Doble B, Xie F, Blackhouse G, Campbell K, Kaulback K, Chandra K, Goeree R. Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based analysis (part B). Ontario Health Technology Assessment Series 2012;12(14):1-62.
  • Blackhouse G, Assasi N, Xie F, Marshall J, Irvine EJ, Gaebel K, Campbell K, Hopkins R, O’Reilly D, Tarride JE, Goeree R. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF drugs for refractory Crohn’s Disease. Journal of Crohn’s and Colitis 2012;6(1):77-85.
  • Tarride J-E, Haq M, Taylor V, Sharma AM, Nakhai-Pour HR, O’Reilly D, Xie F, Dolovich L, Goeree R. Health status, hospitalization, day procedures and physician costs associated with body mass index (BMI) levels in Ontario, Canada. ClinicoEconomics and Outcomes Research 2012;4:21-30.
  • Zhang XH, Li SC, Xie F, Lo NN, Yang KY, Yeo SJ, Fong KY, Thumboo J. An exploratory study of response shift in health-related quality of life and utility assessment among patients with osteoarthritis undergoing total knee replacement surgery in a tertiary hospital in Singapore. Value Health 2012;15(1 Suppl):S72-8.
  • Tarride JE, Haq M, O’Reilly DJ, Bowen JM, Xie F, Dolovich L, Goeree R. The excess burden of osteoarthritis in the province of Ontario, Canada. Arthritis & Rheumatism 2012;64(4):1153-61.
  • Blackhouse G, Xie F, Levine MAH, Campbell K, Assasi N, Gaebel K, O’Reilly D, Tarride J-E, Goeree R. Canadian cost-utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Journal of Population Therapeutics and Clinical Pharmacology 2012;19(2):e166-78.
  • Xie F, Hopkins R, Burke N, Tarride JE, Goeree R. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study. Hospital Practice 2012;40(2):131-7.
  • Shih V, Chan A, Xie F, Ko Y. Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore. Value in Health Regional Issues 2012;1:46-53. (epub available at doi:10.1016/j.vhri.2012.03.013)
  • Shih V, Chan A, Xie F, Ko Y. Health state utility assessment for breast cancer. Value in Health Regional Issues 2012;1:93-7.
  • He J, Bowen JM, Xie F, Goeree R. Cost-effectiveness of antiviral treatments for HBeAg-positive chronic Hepatitis B in Canada. Value in Health 2012 Sep;15(6):894-906.
  • Assasi N, Schwartz L, Tarride JE, Goeree R, Xie F. Economic evaluations conducted for assessment of genetic testing technologies: a systematic review. Genetic Testing and Molecular Biomarkers 2012:16(11):1322-35.
  • Johnston BC, Donen R, Pooni A, Pond J, Xie F, Giglia L, Kam A, Bamber A, Bami K, Patel Y, Gupta R, Guyatt GH. A conceptual framework of health related quality of live impact in acute gastroenteritis. Journal of Pediatric Gastroenterology and Nutrition 2012 [epub ahead of print Nov 6].
  • Tarride J-E, Burke N, von Keyserlingk C, O’Reilly D, Xie F, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. Clinicoeconomics and Outcomes Research 2012;4:287-98.
  • Assasi N, Xie F, Blackhouse G, Gaebel K, Robertson D, Hopkins R, Healey JS, Goeree R. Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis. Journal of Interventional Cardiac Electrophysiology 2012;35(3):259-75.
  • Puhan MA, Akl EA, Bryant D, Xie F, Apolone G, Riet G. Discussing study limitations in reports of biomedical studies- the need for more transparency. Health and Quality of Life Outcomes 2012; 10:23 doi:10.1186/1477-7525-10-23.
  • Sehatzadeh S, Doble B, Xie F, Blackhouse G, Campbell K, Kaulback K, Chandra K, Goeree R. Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based Analysis (part B). Ontario Health Technology Assessment Series. 2012;12(14):1-62.
  • Xie F, Ye H, Zhang Y, Liu X, Lei T, Li SC. Extension from inpatients to outpatients: validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis. International Journal of Rheumatic Diseases 2011;14(2):206-210.
  • Pullenayegum EM, Tarride J-E, Xie F, O’Reilly D. Calculating utility decrements associated with an adverse event: marginal Tobit and CLAD coefficients should be used with caution. Medical Decision Making 2011;31(6):790-9.
  • Chow BJW, Freeman MR, Bowen JM, Levin L, Hopkins RB, Provost Y, Tarride J-E, Dennie C, Cohen EA, Marcuzzi D, Iwanochko R, Moody AR, Paul N, Parker JD, O’Reilly DJ, Xie F, Goeree R. Ontario Multi-detector Computed Tomographic Coronary Angiography Study (OMCAS): field evaluation of diagnostic accuracy. Archives of Internal Medicine 2011;171(11):1021-1029.
  • Chow BJW, Freeman MR, Bowen JM, Levin L, Hopkins RB, Provost Y, Tarride J-E, Dennie C, Cohen EA, Marcuzzi D, Iwanochko R, Moody AR, Paul N, Parker JD, O’Reilly DJ, Xie F, Goeree R. Using the appropriate fishing net for computed tomographic coronary angiography in daily clinical practice. Archives of Internal Medicine 2011;171(16):1512-3.
  • O’Reilly DJ, Xie F, Pullenayegum E, Gerstein HC, Greb J, Blackhouse GK, Tarride JE, Bowen J, Goeree R. Estimation of the impact of diabetes-related complication on quality of life for patients with type 2 diabetes in Ontario, Canada. Quality of Life Research 2011;20(6):939-943.
  • von Keyserlingk C, Hopkins R, Anastasilakis, Toulis K, Goeree R, Tarride J-E, O’Reilly D, Xie F. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: A meta-analysis. Seminars in Arthritis and Rheumatism 2011;41(2):178-86.
  • Tarride J-E, Blackhouse G, DeRose G, Bowen JM, Nakhaipour H, O’Reilly D, Xie F, Novick T, Hopkins R, Goeree R. Should endovascular repair be reimbursed for low risk abdominal aortic aneurysm patients? Evidence from Ontario, Canada. International Journal of Vascular Medicine 2011 (available June 24: doi: 10.1155/2011/308685).
  • Gaebel K, McIvor RA, Xie F, Blackhouse G, Robertson D, Assasi N, Hernandez P, Goeree R. Triple Therapy for a Management of COPD: A Review. COPD 2011 8(3):206-43.
  • Goeree R, He J, O’Reilly D, Tarride J-E, Xie F, Lim M, Burke N. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. ClinicoEconomics and Outcomes Research 2011;3:89-104.
  • Xie F, Bowen JM, Sutherland CS, Burke N, Blackhouse G, Tarride JE, O’Reilly D, Goeree R. Using Health Technology Assessment to Support Evidence-Based Decision Making in Canada: An Academic Perspective. Expert Review of Pharmacoeconomics & Outcomes Research 2011;11(5):513-21.
  • O’Reilly D, Gaebel K, Xie F, Tarride J-E, Goeree R. Health economic evaluations help inform payers of the best use of scarce healthcare resources. International Journal of Circumpolar Health 2011;70(4):419-27.
  • Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskeletal Disorders 2011;12(1):209.
  • Xie F, Lo NN, Tarride JE, O’Reilly D, Goeree R, Lee HP. Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a two-year observational study. European Journal of Health Economics 2010;11(1):27-34.
  • Tarride JE, Burke N, Bischof M, Hopkins RB, Goeree L, Campbell K, Xie F, O’Reilly D, Goeree R. A review of health utilities across conditions common in pediatric and adult populations. Health and Quality of Life Outcomes 2010;8(12).
  • Tarride JE, Hopkins R, Blackhouse G, Bowen JM, Bischof M, Von Keyserlingk C, O’Reilly D, Xie F, Goeree R. A review of methods used in long-term cost-effectiveness models of diabetes treatment. Pharmacoeconomics 2010;28(4):255-277.
  • Pullenayegum EM, Tarride JE, Xie F, Goeree R, Gerstein H, O’Reilly D. Analysis of health utility data when some subjects attain the upper bound of 1: Are tobit and clad models suitable for the analysis of health utility data? Value in Health 2010;13(4):487-494.
  • Gaebel K, Blackhouse G, Campbell K, Robertson D, Xie F, Assasi N, Chalk C, Levine M, Goeree R. Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a sys­tematic review and meta-analysis. Open Medicine 2010;4(3)e154-e166.
  • Goeree R, Tarride JE, O’Reilly D, Xie F, Bowen J, Blackhouse G, Hopkins R. Conditionally funded field evaluations: PATHs coverage with evidence development program for Ontario. Value in Health 2010;13 Suppl 1:S8-11.
  • Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R. Patient outcomes after anti TNF-alpha drugs for Crohn’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 2010;10(2):163-175.
  • Blackhouse G, Gaebel K, Xie F, Campbell, Assasi N, Tarride J-E, O’Reilly D, Chalk C, Levine M, Goeree R. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Effectiveness and Resource Allocation 2010:8:14.
  • Xie F, Lo NN, Pullenayegum EM, Tarride JE, O’Reilly DJ, Goeree R, Lee HP. Evaluation of health outcomes in osteoarthritis patients after total knee replacement: a two-year follow-up. Health and Quality of Life Outcomes 2010;8(1):87.
  • Goeree R, O’Reilly D, Hopkins R, Blackhouse G, Tarride JE, Xie F, Lim M. General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals. Expert Review of Pharmacoeconomics & Outcomes Research 2010;10(4):379-84.
  • Johnston BC, Thorlund K, Schunemann HJ, Xie F, Murad MH, Montori VM, Guyatt GH. Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units. Health and Quality of Life Outcomes 2010;8:116.
  • Xie F, Pullenayegum EM, Li SC, Hopkins R, Thumboo J, Lo NN. Use of a disease-specific Instrument in economic evaluations: mapping Western Ontario and McMaster Universities Osteoarthritis Index onto the EQ-5D utility. Value in Health 2010;13(8):873-978.
  • Blackhouse G, Hopkins R, Bowen JM, DeRose G, Novick T, Tarride J-E, O’Reilly D, Xie F, Goeree R. A cost-effectiveness model comparing endovascular repair to open surgical repair of abdominal aortic aneurysms in Canada. Value in Health 2009;12(2):245-252.
  • Xie F, Despiegel N, Danchenko N, Hansen K. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice 2009;13(1):59-69.
  • Tarride JE, Lim ME, Bowen JM, McCarron CE, Blackhouse G, Hopkins R, O’Reilly D, Xie F, Goeree R. In search of the evidentiary foundation of published Canadian economic evaluations (2001-2006). International Journal of Technology Assessment in Health Care 2009;25(2):214-221.
  • Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride J-E, Xie F, O’Reilly D. Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Canadian Journal of Diabetes 2009;33(1):35-45.
  • Bowen JM, Patterson LL, O’Reilly DJ, Hopkins RB, Blackhouse G, Burke N, Xie F, Tarride J-E, Goeree R. Conditionally funded field evaluations and practical trial design within a HTA framework. Journal of the American College of Radiology 2009;6(5):324-331.
  • Xie F, O’Reilly D, Ferrusi I, Blackhouse G, Bowen JM, Tarride J-E, Goeree R. Illustrating economic evaluation of diagnostic technologies: Comparing helicobacter pylori screening strategies in prevention of gastric cancer in Canada. Journal of the American College of Radiology 2009;6(5):317-323.
  • Tarride J-E, Blackhouse G, Bischof M, McCarron EC, Lim M, Ferrusi I, Xie F, Goeree R. Approaches to economic evaluations of healthcare technologies. Journal of the American College of Radiology 2009;6(5):307-316.
  • Goeree R, Levin L, Chandra K, Bowen JM, Blackhouse G, Tarride JE, Burke N, Bischof M, Xie F, O’Reilly D. Health technology assessment and primary data collection for reducing decision making uncertainty. Journal of the American College of Radiology 2009;6(5):332-342.
  • Xie F, Blackhouse G, Assasi N, Campbell K, Levin M, Bowen J, Tarride JE, Pi D, Goeree R. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura. Clinical Therapeutics 2009;31(5):1082-1091.
  • Goeree R. Lim M, Hopkins R, Blackhouse G, Tarride J-E, Xie F, O’Reilly D. Excess risk of mortality and complications associated with newly diagnosed cases of diabetes in Ontario, Canada. Canadian Journal of Diabetes 2009;33(2):93-104.
  • Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness and Resource Allocation 2009;7:20.
  • Luo N, Seng BK, Xie F, Li SC, Thumboo J. Validation of the Schizophrenia Quality of Life Scale (SQLS) in Asian Patients with Schizophrenia in Singapore. Quality of Life Research 2008;17:115-122.
  • Xie F, Luo N, Blackhouse G, Goeree R, Lee HP. Cost Effectiveness Analysis of Helicobacter Pylori Screening in Prevention of Gastric Cancer in Chinese. International Journal of Technology Assessment in Health Care 2008;24:87-95.
  • Xie F, Thumboo J, Fong KY, Lo NN, Yeo SJ, Yang KY, Li SC. A Study on Indirect and Intangible Costs for Patients with Knee Osteoarthritis in Singapore. Value in Health 2008;11:S-84-S90.
  • Wee HL, Li SC, Xie F, Zhang XH, Luo N, Feeny D, Cheung YB, Machin D, Fong KY, Thumboo J. Validity, Feasibility and Acceptability of Time Trade-off and Standard Gamble Assessments in Health Valuation Studies: A Study in A Multiethnic Asian Population in Singapore. Value in Health 2008;11:S3-S10.
  • Zhang XH, Xie F, Wee HL, Thumboo J, Li SC. Applying the Expectancy-Value Model to Understand Health Values. Value in Health 2008;11:S61-S68.
  • Xie F. The Need for Standardization: A Literature Review of Indirect Costs of Rheumatoid Arthritis and Osteoarthritis. Arthritis & Rheumatism 2008;59(7):1027-1033.
  • Xie F, Li SC, Goeree R, Tarride JE, O’Reilly D, Lo NN, Yeo SJ, Yang KY, Thumboo J. Validation of Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in Patients Scheduled for Total Knee Replacement. Quality of Life Research 2008;17:595-601.
  • Xie F, Luo N, Lee HP. Cost Effectiveness Analysis of Population-Based Serology Screening and 13C-Urea Breath Test for Helicobacter pylori to Prevent Gastric Cancer: A Markov Model. World Journal of Gastroenterology 2008;14(19):3021-3027.
  • Xie F, Lo NN, Lee HP, Cieza A, Li SC. Validation of the International Classification of Functioning, Disability, and Health (ICF) Brief Core Set for Osteoarthritis. Scandinavian Journal of Rheumatology 2008;37(6):450-461.
  • Wee HL, Li SC, Zhang XH, Xie F, Feeny D, Luo N, Cheung Y-B, Machin D, Fong K-Y, Thumboo J. Are symbols useful and culturally acceptable in health-state valuation studies? An exploratory study in multi-ethnic Asian population. Patient Preference and Adherence 2008;2:271-276.
  • Tarride J-E, McCarron CE, Lim M, Bowen JM, Blackhouse G, Hopkins R, O’Reilly D, Xie F, Goeree R. Economic Evaluations Conducted by Canadian Health Technology Assessment Agencies: Where Do We Stand? International Journal of Technology Assessment in Health Care 2008;24(4):437-444.
  • Xie F, Thumboo J, Lo NN, Yeo SJ, Yang KY, Yeo W, Chong HC, Fong KY, Li SC. Cross-Cultural Adaptation and Validation of Singapore English and Chinese   Versions of the Lequesne Algofunctional Index of Knee in Asians with Knee Osteoarthritis in Singapore. Osteoarthritis Cartilage 2007;15:19-26.
  • Xie F, Thumboo J, Fong KY, Lo NN, Yeo SJ, Yang KY, Li SC. Direct and Indirect Costs of Osteoarthritis: A Comparative Study among Multiethnic Asian Patients with Osteoarthritis in Singapore. Journal of Rheumatology 2007;34:165-171.
  • Xie F, Thumboo J, Li SC. True Difference or Something Else? Problems in Cost of Osteoarthritis Studies. Seminars in Arthritis and Rheumatism 2007;37:127-132.
  • Xie F, Li SC, Lo NN, Yeo SJ, Yang KY, Thumboo J. Cross-Cultural Adaptation and Validation of Singapore English and Chinese Versions of the Oxford Knee Score (OKS) in Knee Osteoarthritis Patients Undergoing Total Knee Replacement. Osteoarthritis and Cartilage 2007;15:1019-1024.
  • Xie F, Li SC, Luo N, Lo NN, Yeo SJ, Yang KY, Fong KY, Thumboo J. A Comparison of EQ-5D and SF-6D in Multiethnic Asian Patients with Knee Osteoarthritis in Singapore. Arthritis & Rheumatism 2007;57:1043-1049.
  • Xie F, Lo NN, Lee HP, Cieza A, Li SC. Validation of the Comprehensive ICF Core Set for Osteoarthritis from the Singaporean Perspective. Journal of Rheumatology 2007;34:2301-2307.
  • Xie F, Thumboo J, Fong KY, Lo NN, Yeo SJ, Yang KY, Li SC. Are They Relevant? A Critical Evaluation of the International Classification of Functioning, Disability and Health Core Sets for Osteoarthritis from the Perspective of Patients with Knee Osteoarthritis in Singapore. Annals of the Rheumatic Diseases 2006;65:1067-1073.
  • Xie F, Li SC, Fong KY, Lo NN, Yeo SJ, Yang KY, Thumboo J. What Health Domains & Items Are Important to Patients with Knee Osteoarthritis? A Focus Group Study in a Multiethnic Urban Asian Population. Osteoarthritis Cartilage 2006;14:224-230.
  • Xie F, Li SC, Roos E, Fong KY, Lo NN, Yeo SJ, Yang KY, Yeo W, Chong HC, Thumboo J. Cross-Cultural Adaptation and Validation of Singapore English and Chinese Versions of the Knee Injury and Osteoarthritis Outcome Score (KOOS) in Asians with Knee Osteoarthritis in Singapore. Osteoarthritis Cartilage 2006;14:1098-1103.
  • Wee HL, Li SC, Xie F, Zhang XH, Luo N, Cheung YB, Machin D, Fong KY, Thumboo J. Are Asians Comfortable with Discussing Death in Health Valuation Studies? A Study in Multi-ethnic Singapore. Health and Quality of Life Outcomes 2006;4:93-105.
  • Luo N, Xie F, Wang QN, Li SC. Does Education Level Affect the Measurement of Health Utilities? China Journal of Pharmaceutical Economics 2006;3:79-86.
  • Luo, N, Fones CSL, Lim SE, Xie F, Thumboo J, Li SC. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation of English version in Singapore. Quality of Life Research 2005;14:1181-1186.
  • Xie F, Tan CH, Li, SC. Are They Being Used Safely? A Retrospective Cross-sectional Tertiary Health Care Survey of Selective Serotonin Reuptake Inhibitors Prescribing Practice in Singapore. Human Psychopharmacology: Clinical & Experimental 2005;20:1-7.
  • Xie F, Li SC, Thumboo J. Do the Health-related Quality of Life Domains and Items in Knee and Hip Osteoarthritis Vary in Importance Across Social-cultural Contexts? A Qualitative Systematic Literature Review. Seminars in Arthritis and Rheumatism 2005;34(6):793-804.